Stellar Biotechnologies Inc. (SBOTF)

[Schris]

Stellar’s $12M raise sets stage for drug rollout

Dear Stellar Biotechnologies Supporter:

See below today’s story in Pacific Coast Business Times


Stellar’s $12M raise sets stage for drug rollout
By Stephen Nellis on October 11, 2013

Port Hueneme-based Stellar Biotechnologies has closed a $12 million round of financing and acquired a license for what could one day be its first drug.

Stellar gained notoriety in the research world by snatching up a facility inside the Port of Hueneme gates during a round of base closings in the late 1990s. It used that facility to sustainably cultivate giant keyhole limpets. The mollusks produce what is known as keyhole limpet hemocyanin, or KLH, a carrier protein for vaccines that previously had to be harvested from the wild.

Frank Oakes, Stellar’s CEO, said the company has been focused on moving up the value chain. In the past, it provided raw KLH material that other companies would then purify and sell to researchers for integration into therapies. Stellar has developed the ability purify its proteins in house. And in July, it acquired a license to patents covering a potential treatment for infections of Clostridium difficile, or C. diff, a common infection in hospitals. Read the full story…..

http://www.pacbiztimes.com/2013/10/11/stellars-12m-raise-sets-stage-for-drug-rollout/


Learn more about KLH and its vital importance to vaccines and immunology, visit www.KLHsite.com. Read more about Stellar at www.stellarbiotechnologies.com.


About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (TSX-V: KLH) (US OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

To receive regular updates, enter email at http://stellarbiotechnologies.com/contact/

Visit www.StellarBiotech.com and the KLH knowledge base www.KLHSite.com.

Contacts:

Frank Oakes
President and CEO
Phone [phone]
[e-mail]

Investor Relations:
MZ Group
Mark A. McPartland
Senior Vice President
Phone: [phone]
[e-mail]
Web: www.mzgroup.us

Forward Looking Statements
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.